FLASCO 2025 Clinical Oncology Series - Antibody-Drug Conjugates

Join us for an in-depth exploration of the latest advancements in Antibody-Drug Conjugates (ADCs), where leading experts will present groundbreaking research, emerging clinical trial data, and innovative therapeutic strategies. This dynamic program is designed to deepen your understanding of ADCs and their evolving role in modern oncology, with a focus on improving patient outcomes through evidence-based best practices. 

Engage with thought leaders, collaborate with peers, and gain valuable insights into the current challenges and future directions in ADC therapy. Through a comprehensive and practical agenda, attendees will leave equipped with the knowledge and tools to elevate their clinical practice and enhance patient care.

Please note: Industry participation is limited to exhibit sponsors only.